Neurocrine Biosciences (NBIX) Competitors $116.18 +0.58 (+0.50%) Closing price 04:00 PM EasternExtended Trading$117.62 +1.44 (+1.24%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, UTHR, BMRN, INCY, EXEL, RGEN, EXAS, HALO, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exelixis (EXEL), Repligen (RGEN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Exelixis Repligen Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Do insiders & institutionals have more ownership in ALNY or NBIX? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ALNY or NBIX? Alnylam Pharmaceuticals presently has a consensus target price of $312.30, suggesting a potential upside of 7.43%. Neurocrine Biosciences has a consensus target price of $165.24, suggesting a potential upside of 42.94%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.76Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the MarketBeat Community believe in ALNY or NBIX? Alnylam Pharmaceuticals received 128 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.50% of users gave Neurocrine Biosciences an outperform vote while only 76.28% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes115876.28% Underperform Votes36023.72% Neurocrine BiosciencesOutperform Votes103077.50% Underperform Votes29922.50% Which has more risk and volatility, ALNY or NBIX? Alnylam Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Which has better earnings and valuation, ALNY or NBIX? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B16.74-$278.16M-$2.17-133.96Neurocrine Biosciences$2.36B4.89$341.30M$3.2935.14 Does the media favor ALNY or NBIX? In the previous week, Alnylam Pharmaceuticals had 45 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 57 mentions for Alnylam Pharmaceuticals and 12 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.11 beat Alnylam Pharmaceuticals' score of 0.69 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 22 Very Positive mention(s) 9 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ALNY or NBIX more profitable? Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Neurocrine Biosciences 14.49%13.38%9.73% SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.53B$3.05B$5.74B$8.28BDividend YieldN/A1.54%4.55%4.02%P/E Ratio35.1430.1524.7219.36Price / Sales4.89460.58397.6793.27Price / Cash34.35168.6838.1634.64Price / Book4.454.347.154.51Net Income$341.30M-$71.72M$3.20B$247.14M7 Day Performance5.38%0.33%2.84%3.64%1 Month Performance-0.26%-7.37%6.99%-2.30%1 Year Performance-17.58%-20.93%15.59%4.93% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8877 of 5 stars$116.18+0.5%$165.24+42.2%-18.3%$11.58B$2.36B35.311,200Positive NewsALNYAlnylam Pharmaceuticals4.5739 of 5 stars$253.11+4.7%$304.26+20.2%+98.4%$32.77B$2.25B-116.642,230Analyst UpgradeNews CoverageBIIBBiogen4.8506 of 5 stars$143.54+2.9%$213.33+48.6%-35.1%$21.01B$9.68B12.838,720News CoveragePositive NewsUTHRUnited Therapeutics4.4039 of 5 stars$322.94+5.1%$388.25+20.2%+34.5%$14.50B$2.88B14.18980Positive NewsBMRNBioMarin Pharmaceutical4.9852 of 5 stars$71.55+3.0%$94.00+31.4%-15.4%$13.65B$2.85B32.523,401Analyst RevisionINCYIncyte4.8145 of 5 stars$62.01-8.6%$75.25+21.4%+10.2%$12.00B$4.24B229.682,617Analyst ForecastHigh Trading VolumeEXELExelixis4.6765 of 5 stars$37.02+1.0%$37.59+1.5%+58.6%$10.36B$2.17B20.921,147Positive NewsRGENRepligen4.7524 of 5 stars$152.81+1.5%$181.00+18.4%-26.7%$8.56B$634.44M-299.632,020EXASExact Sciences4.3997 of 5 stars$45.18+0.4%$70.83+56.8%-24.2%$8.39B$2.76B-8.116,600Positive NewsHALOHalozyme Therapeutics4.2798 of 5 stars$62.95+1.1%$62.78-0.3%+59.7%$7.75B$1.02B18.35390Positive NewsMDGLMadrigal Pharmaceuticals3.9569 of 5 stars$342.44-1.7%$378.44+10.5%+39.6%$7.56B$180.13M-13.6590Positive News Remove Ads Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Incyte Competitors Exelixis Competitors Repligen Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts